Search Results

1 - 10 of 117 items :

  • pathologic complete response x
Clear All
Induction chemotherapy, chemoradiotherapy and consolidation chemotherapy in preoperative treatment of rectal cancer - long-term results of phase II OIGIT-01 Trial

standard of care for these patients. Still, the prognosis remains largely unsatisfactory due to a high rate of distant relapse, which is the most common cause of death. 1 The results of two meta-analyses suggest that the pathological stage of the disease and/or the rate of tumour reduction (pathohistological tumour regression - TRG) after pre-operative treatment are predictive factors for disease-free survival. A particularly low risk of recurrence of the disease has a subgroup of patients with a complete pathohistological response (pCR). 2 , 3 With standard 5-FU

Open access
Preoperative intensity-modulated chemoradiation therapy with simultaneous integrated boost in rectal cancer: 2-year follow-up results of phase II study

with standard 3-dimensional conformal radiotherapy (3D CRT) in rectal cancer 6 , 7 , 8 , 9 , this novel radiation technique has been used in several prospective phase II studies with the aim of improving the treatment outcome in LARC. The treatment intensification consisted of a dose escalation with a simultaneous integrated boost (SIB), with or without the use of an additional drug alongside standard concomitant capecitabine. 10 , 11 , 12 , 13 , 14 , 15 Researchers report an encouraging rate of pathologic complete response (pCR) and local control (LC), but with

Open access
Impact of genetics on neoadjuvant therapy with complete pathological response in metastatic colorectal cancer: Case report and review of the literature

process. Molecular targeted therapy is based on the specific genetics of every neoplastic process which implies individualized treatment according to detected genetic mutations. The role of some biomarkers, such as the KRAS (Kirsten rat sarcoma) gene mutation, is evaluated in determining molecular targeted therapy [ 6 ]. Neoadjuvant chemotherapy response is very important for disease-free and overall survival, and in the era of effective chemotherapy, various criteria for tumor response are established [ 10 ]. A complete pathologic response of both primary and

Open access
Prognostic significance of tumor regression in locally advanced rectal cancer after preoperative radiochemotherapy

Introduction Combined chemoradiotherapy (CRT) followed by total mesorectal excision (TME) is the standard treatment for patients with locally advanced rectal cancer. 1 This approach led to significantly enhanced tumor control, with local recurrence rates of < 10%. Preoperative chemotherapy induces changes in both gross appearance of the surgical specimen and its pathological features. Pathologic tumor response to therapy is an important prognostic factor for long-term prognosis. Moreover, patients with complete pathologic response to neoadjuvant

Open access
Evaluation of MRI accuracy after primary systemic therapy in breast cancer patients considering tumor biology: optimizing the surgical planning

(BCS). However, the primary goal of PST is to achieve pathologic complete response (pCR) prior to surgical treatment, which has been shown to predict favorable prognosis. 3 , 4 , 5 Over the past few years, the highest use of PST was seen among HER2-positive and triple-negative breast cancer (TNBC) patients. 6 Women with these tumor subtypes have the highest rates of BCS and pCR after PST. 7 Furthermore, prognostic impact of pCR is highest in HER2-positive and TNBC. 8 , 9 , 10 Currently, although the nuclear imaging techniques are promising, magnetic

Open access
Quantitative aspects of diffusion-weighted magnetic resonance imaging in rectal cancer response to neoadjuvant therapy

characteristics are summarized in Table 1 . Table 1 The patients’ clinical characteristics and patohystologic characteristics of the tumor All pCR non-pCR Average age , years 59.6 ±11.5 58.5 ±11.2 59.9 ±11.8 Gender = number of individuals; CRT = chemoradiotherapy; pCR = pathologic complete response    Male 18 5 13    Female 15 2 13 Clinical T stage pre-CRT (MRI classification) = number of individuals; CRT = chemoradiotherapy; pCR = pathologic complete response    T2 3 1 2

Open access
Preoperative treatment with radiochemotherapy for locally advanced gastroesophageal junction cancer and unresectable locally advanced gastric cancer

advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27: 851-6. 16. Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004; 22: 2774-80. 17. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J

Open access
Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies

-9. 4. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006; 24: 1037-44. 5. Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A, et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European cooperative trial in operable breast

Open access
Neoadjuvant gemcitabine and docetaxel in primary breast angiosarcoma revealed complete pathological remission

; 22: 1706-12. 22. Shkoukani MA, Carron MA, Tulunay O, Kucuk O, Lin HS. Angiosarcoma of the scalp with complete response to a biweekly gemcitabine and docetaxel (GEMDOC) chemotherapy regimen. Ear Nose Throat J. 2011; 90:E26-9. 23. Wilson R, Glaros S, Brown RK, Michael C, Reisman D. Complete radiographic response of primary pulmonary angiosarcomas following gemcitabine and taxotere. Lung Cancer. 2008; 61:131-6.

Open access
Phase I study of integrating PET/CT and dose-escalated intensity modulated radiation therapy using a simultaneous integrated boost technique for thoracic esophageal cancer

al. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys. 2005; 4:1053-9. 9. Zhong X, Yu J, Zhang B, Mu D, Zhang W, Li D, et al. Using 18F-fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2009; 73: 136-41. 10. Han D, Yu J, Yu Y, Zhang G, Zhong X, Lu J, et al. Comparison of (18)F-fluorothymidine and

Open access